Hung Trinh: Lutathera Cuts Risk of Death by 72% in Neuroendocrine Tumor Treatment
Hung Trinh, Director of Process Development and MFG Science and Technology at Vyriad, posted on LinkedIn:
“NETTER-2 Trial: Lutathera Cuts Risk of Death by 72% in Neuroendocrine Tumor Treatment
Novartis announced groundbreaking results from the NETTER-2 trial, showing Lutathera plus octreotide LAR significantly reduces the risk of death by 72% in patients with advanced GEP neuroendocrine tumors. This first successful Phase III trial of radioligand therapy (RLT) in a first-line setting marks a major advancement in cancer treatment.
In a landmark development for cancer therapy, the Phase III NETTER-2 trial, led by Novartis, demonstrated that Lutathera® plus octreotide LAR significantly extends median progression-free survival to 22.8 months and reduces disease progression or death by 72% in advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
The study’s findings, presented at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, mark the first successful use of radioligand therapy (RLT) as a first-line treatment.”
Proceed to the article.
Source: Hung Trinh/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023